Terminated PHASE2 INTERVENTIONAL 1-arm NCT00301405

Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain

Sponsor: Celgene Corporation

Conditions Chronic Prostatitis Pelvic Pain

Interventions Thalidomide

Updated 7 times since 2017 Last updated: Aug 1, 2013 Started: Mar 31, 2006 Primary completion: Nov 30, 2006 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study closed. Difficult enrollment of patients with prostatitis.

Other terminated trials from Celgene Corporation

More terminations from Celgene Corporation

A PHASE2 clinical study on Chronic Prostatitis and Pelvic Pain, this trial is terminated or withdrawn. The trial is conducted by Celgene Corporation and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Terminated PHASE2
Sep 2024 — Jan 2026 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
Corewell Health East
Kenneth Peters, MD

Data source: Corewell Health East

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Royal Oak, United States